Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407
Wanda L Salzer, Tamekia L Jones, Meenakshi Devidas, Joanne M Hilden, Naomi Winick, Stephen Hunger, William L Carroll, Bruce Camitta, ZoAnn E Dreyer, Wanda L Salzer, Tamekia L Jones, Meenakshi Devidas, Joanne M Hilden, Naomi Winick, Stephen Hunger, William L Carroll, Bruce Camitta, ZoAnn E Dreyer
Abstract
Background: Infants (<366 days of age) with acute lymphoblastic leukemia (ALL) have a poor prognosis. Most treatment failures occur within 6-9 months of diagnosis, primarily from relapse.
Procedure: The Children's Oncology Group P9407 study was designed to test if early intensified treatment would improve outcome for infants with ALL. Due to a significant number of early deaths (< 90 days from enrollment), Induction therapy was amended three times. Cohorts 1 + 2 (n = 68), received identical Induction therapy except for reduced daunorubicin dose in Cohort 2. Cohort 3 (n = 141) received prednisone (40 mg/m(2)/day) instead of dexamethasone (10 mg/m(2)/day) and short infusion daunorubicin (30 minutes) instead of continuous infusion (48 hours), as well as additional supportive care measures throughout therapy.
Results: Early deaths occurred in 17/68 (25%) infants in Cohorts 1 + 2 and 8/141 (5.7%) infants in Cohort 3 (P < 0.0001). Among infants ≤90 days of age at diagnosis, early death occurred in 10/17 (58.8%) in Cohorts 1 + 2 and 4/27 (14.8%) in Cohort 3 (P = 0.006). Among infants >90 days of age at diagnosis, early death occurred in 7/51 (13.7%) in Cohorts 1 + 2 and 4/114 (3.5%) in Cohort 3 (P = 0.036). Bacterial, viral, and fungal infections were more common in Cohorts 1 + 2 versus Cohort 3.
Conclusions: Early morbidity and mortality for infants with ALL were reduced by substitution of prednisone (40 mg/m(2)/day) for dexamethasone (10 mg/m(2)/day), the delivery of daunorubicin over 30 minutes instead of a continuous infusion for 48 hours, and the provision of more specific supportive care measures.
Conflict of interest statement
Conflict of interest: Nothing to declare.
Copyright © 2012 Wiley Periodicals, Inc.
Figures

Source: PubMed
Nadchodzące badania kliniczne
-
Artvin Coruh UniversityJeszcze nie rekrutacjaChoroba zęba Charcota-Mariego (CMT)Turcja (Türkiye)
-
University of Management and Technology LahoreJeszcze nie rekrutacjaChoroba zwyrodnieniowa stawu kolanowegoPakistan
-
Regeneron PharmaceuticalsRekrutacyjnyZaawansowane guzy liteStany Zjednoczone
-
Kirsehir Ahi Evran UniversitesiJeszcze nie rekrutacjaPrzemoc wobec dzieci | Edukacji Pielęgniarskiej | Zaniedbywanie dzieci | Wykorzystywanie seksualne dzieci
-
Lokman Hekim UniversityJeszcze nie rekrutacjaEdukacji PielęgniarskiejTurcja (Türkiye)
-
Imagion Biosystems, Inc.RekrutacyjnyHER2-dodatni rak piersiStany Zjednoczone
-
Ankara City Hospital BilkentRekrutacyjnyStrach przed porodem | Cesarskie cięcie | LABOR PAİNTurcja (Türkiye)
-
Örebro University, SwedenRekrutacyjny
-
Oorja Bio, Inc.Rekrutacyjny
-
Cairo UniversityJeszcze nie rekrutacjaRadikulopatia szyjna korzenia nerwu C6Egipt
-
Indiana UniversityRekrutacyjnyZapobieganie ciąży | Męska antykoncepcja | Urządzenie antykoncepcyjne | Prevention of Semen Exposure During IntercourseStany Zjednoczone
-
Tianjin Medical University Cancer Institute and...Jeszcze nie rekrutacjaChłoniak z komórek płaszcza (MCL) | Nawrotowy/Oporny na leczenie chłoniak z komórek płaszcza (MCL)Chiny